BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

819 related articles for article (PubMed ID: 10638019)

  • 1. Pathogenetic factors and clinical elements in ascites and hepatorenal syndrome during liver cirrhosis.
    Gentilini P; Laffi G; La Villa G; Raggi VC
    Ann Ital Med Int; 1999; 14(4):264-84. PubMed ID: 10638019
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fluid retention in cirrhosis: pathophysiology and management.
    Kashani A; Landaverde C; Medici V; Rossaro L
    QJM; 2008 Feb; 101(2):71-85. PubMed ID: 18184668
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Update on ascites and hepatorenal syndrome.
    Gentilini P; Vizzutti F; Gentilini A; Zipoli M; Foschi M; Romanelli RG
    Dig Liver Dis; 2002 Aug; 34(8):592-605. PubMed ID: 12502217
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Refractory ascites: pathogenesis, definition and therapy of a severe complication in patients with cirrhosis.
    Salerno F; Guevara M; Bernardi M; Moreau R; Wong F; Angeli P; Garcia-Tsao G; Lee SS
    Liver Int; 2010 Aug; 30(7):937-47. PubMed ID: 20492521
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatorenal syndrome.
    Gattoni A; Marotta F; Vangieri B; Pisani G; Cristiano F
    Clin Ter; 2004 Sep; 155(9):375-89. PubMed ID: 15700631
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Type-2 hepatorenal syndrome and refractory ascites: role of transjugular intrahepatic portosystemic stent-shunt in eighteen patients with advanced cirrhosis awaiting orthotopic liver transplantation.
    Testino G; Ferro C; Sumberaz A; Messa P; Morelli N; Guadagni B; Ardizzone G; Valente U
    Hepatogastroenterology; 2003; 50(54):1753-5. PubMed ID: 14696397
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ascites and hepatorenal syndrome: pathogenesis and treatment strategies.
    Ginès P; Arroyo V; Rodés J
    Adv Intern Med; 1998; 43():99-142. PubMed ID: 9506180
    [No Abstract]   [Full Text] [Related]  

  • 8. Ascites in liver diseases.
    Gentilini P; Laffi G
    Ann Ital Med Int; 1991; 6(1 Pt 2):148-55. PubMed ID: 1742150
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatorenal syndrome.
    Biswas KD; Jain AK
    Trop Gastroenterol; 2002; 23(3):113-6. PubMed ID: 12693150
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular adsorbent recirculating system is ineffective in the management of type 1 hepatorenal syndrome in patients with cirrhosis with ascites who have failed vasoconstrictor treatment.
    Wong F; Raina N; Richardson R
    Gut; 2010 Mar; 59(3):381-6. PubMed ID: 19710033
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiovascular, renal, and neurohumoral responses to single large-volume paracentesis in patients with cirrhosis and diuretic-resistant ascites.
    Peltekian KM; Wong F; Liu PP; Logan AG; Sherman M; Blendis LM
    Am J Gastroenterol; 1997 Mar; 92(3):394-9. PubMed ID: 9068457
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathogenesis of ascites in cirrhosis and portal hypertension.
    Heneghan MA; Harrison PM
    Med Sci Monit; 2000; 6(4):807-16. PubMed ID: 11208415
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatorenal syndrome.
    Bataller R; Arroyo V; Ginès P; Sort P
    Forum (Genova); 1998; 8(1):62-81. PubMed ID: 9565447
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Review article: Management of ascites and associated complications in patients with cirrhosis.
    Kuiper JJ; de Man RA; van Buuren HR
    Aliment Pharmacol Ther; 2007 Dec; 26 Suppl 2():183-93. PubMed ID: 18081661
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatorenal syndrome and its treatment today.
    Gentilini P; La Villa G; Casini-Raggi V; Romanelli RG
    Eur J Gastroenterol Hepatol; 1999 Sep; 11(9):1061-5. PubMed ID: 10503849
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Natural course and physiopathology of ascites in the cirrhotic patient].
    Bernardi M; Colantoni A; Caraceni P; Sica G; Trevisani F
    Ann Ital Med Int; 1996 Oct; 11 Suppl 2():30S-38S. PubMed ID: 9004818
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Hepatorenal syndrome].
    Mijac D; Kezić A; Stojimirović B
    Srp Arh Celok Lek; 2007; 135(1-2):98-104. PubMed ID: 17503577
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Physiopathology of refractory ascites and the hepatorenal syndrome].
    Arroyo V
    Nefrologia; 2002; 22 Suppl 5():41-6. PubMed ID: 12107916
    [No Abstract]   [Full Text] [Related]  

  • 19. Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome.
    Wong F; Pantea L; Sniderman K
    Hepatology; 2004 Jul; 40(1):55-64. PubMed ID: 15239086
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Refractory ascites: definition, pathogenesis and treatment.
    Laffi G; La Villa G; Pinzani M; Foschi M; Carloni V; Casini Raggi V; Gentilini P
    Ann Ital Med Int; 1993; 8(1):38-46. PubMed ID: 8485009
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.